Eli Lilly anticipates revenue boost in 2023 as it prepares to launch slate of new drugs
Eli Lilly executives are bullish on its prospects for next year as the Indianapolis pharma lifts the cover on its 2023 financial guidance.
Revenues are expected to land between $30.3 billion and $30.8 billion next year, Lilly said on Tuesday, a bump over its expected 2022 revenue between $28.5 billion and $29 billion as reported in the third quarter. Lilly attributed the 2023 gains to “volume-based revenue growth” for existing products, along with up to four possible launches for donanemab, pirtobrutinib, lebrikizumab and mirikizumab. Among those, key Phase III readouts are expected for donanemab in early Alzheimer’s and mirikizumab in Crohn’s disease.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters